Genmab revenue and financials

GMAB · Nasdaq Copenhagen · DKK

Compare Genmab
kr 3,502.00Change from previous close: −0.77%Absolute change: −kr 27.00

Close · November 17, 2026

In the fiscal year ended December 2025, Genmab reported revenue of $3.72B (+19.19% year over year). Net income was $963M, a net margin of 25.9%.

Annual revenue · 2025: $3.72B
  1. $257.1M2016
  2. $381.27M2017
  3. $464.62M2018
  4. $805.46M2019
  5. $1.66B2020
  6. $1.29B2021
  7. $2.09B2022
  8. $2.39B2023
  9. $3.12B2024
  10. $3.72B2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+19.19%
2025 vs 2024
Net income growth
−15.00%
2025 vs 2024
Net margin
25.9%
2024: 36.3%

How Genmab is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue3,7203,1212,3902,0881,2871,660805465381257
Cost of revenue23814333.00.0——————
Gross profit3,4822,9782,3572,0881,2871,660805465381257
Selling, general and administrative62654947838519610851.332.923.714.5
Research and development1,6061,4141,10780163951535822013793.6
Operating income1,2501,0157729024511,036396212220149
EBIT1,2501,0157729024511,036396212220149
EBITDA1,2901,0528029444811,074417225228155
Interest expense61.018.010.05.62.01.61.111.00.50.0
Pre-tax income1,2041,3268171,000599969429248171160
Income tax24119318621514718810421.5-6.4-8.0
Net income9631,133631785452781325226178168
Net income to common shareholders9631,133631785452781325226178168
Basic EPS15.4917.659.6612.006.9111.985.163.692.922.81
Diluted EPS15.3717.539.5811.896.8511.855.113.642.862.72
Average shares (basic)62.264.265.365.465.465.263.061.360.859.9
Average shares (diluted)62.764.765.966.066.065.963.662.062.161.8

Companies in the group: same industry, similar size